Endo recalls one lot of Edex

Published: 7-Mar-2017
Packaging Regulatory

Endo Pharmaceuticals has recalled one lot of Edex (alprostadil for injection) 10mcg to the consumer level, due to lack of sterility assurance

This product recall is due to the detection by the company of a defect in the crimp caps used in the manufacture of the subject product lot.

This defect has the potential to lead to a loss of container closure integrity, which could impact the product’s sterility assurance and may lead to serious adverse events such as infections, both localised at the site of injection and systemically.

To date, Endo has not received adverse event reports related to this recall.

Edex is a prescription only intracavernous injection indicated for the treatment of male erectile dysfunction. The recall applies to the 10mcg strength, packaged in a two pack carton.

Endo states that it takes this issue seriously and is fully committed to ensuring all of its products and packaging meet the highest quality standards.

This Product Recall is being made with the knowledge of the United States Food and Drug Administration (FDA).

  • Companies:
  • Endo Pharmaceuticals
See more

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

Read more
New certification allows accreditation without prior approval

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. SÜDPACK’s greenhouse gas reduction targets validated by the SBTi The company aims to reduce scope 1 & 2 greenhouse gas emissions by 76%, as well as a 25% reduction in scope 3 emissions
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Packaging

SÜDPACK’s greenhouse gas reduction targets validated by the SBTi

The company aims to reduce scope 1 & 2 greenhouse gas emissions by 76%, as well as a 25% reduction in scope 3 emissions
Packaging

How robots enhance the efficiency of pharmaceutical labelling

At ACHEMA 2024 (Hall 4.1, Stand B20), HERMA will demonstrate how robotics make challenging labelling processes more reliable, more cost-efficient and faster
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now